Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pds Biotechnology Corp (PDSB)

Pds Biotechnology Corp (PDSB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Pds Biotechnology Corp 303A College Road East Princeton NJ 08540 USA

www.pdsbiotech.com Employees: 25 P: 800-208-3343

Description:

PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company's products are based on the proprietary Versamune(R) platform technology, which activates and directs the human immune system. PDS Biotechnology Corp, formerly known as Edge Therapeutics Inc., is based in Berkeley Heights, United States.

Key Statistics

Overview:

Market Capitalization, $K 61,725
Enterprise Value, $K 24,675
Shares Outstanding, K 37,409
Annual Sales, $ 0 K
Annual Net Income, $ -42,940 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -10,730 K
EBIT, $ -39,370 K
EBITDA, $ -38,660 K
60-Month Beta 1.85
% of Insider Shareholders 9.50%
% of Institutional Shareholders 26.84%
Float, K 33,855
% Float 90.50%
Short Volume Ratio 0.22

Growth:

1-Year Return -66.05%
3-Year Return -81.67%
5-Year Return -44.44%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 92.28%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.29 on 11/14/24
Next Earnings Date N/A
Earnings Per Share ttm -1.16
EPS Growth vs. Prev Qtr -26.09%
EPS Growth vs. Prev Year 17.14%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 03/18/19

PDSB Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -139.57%
Return-on-Assets % -67.22%
Profit Margin % 0.00%
Debt/Equity 0.55
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.93
Book Value/Share 0.60
Interest Coverage -9.53
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar